Novabay Shares Tank on Impetigo Phase IIb Miss
By Catherine Shaffer
Thursday, November 7, 2013
Novabay Pharmaceuticals Inc. took a pounding in the stock market Thursday after it reported the failure of a Phase IIb study of its impetigo candidate, auriclosene. The study showed that the drug was safe and well tolerated but did not meet the primary clinical endpoint of the trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.